大摩：复星医药将见转机 评级升至“增持” 上调目标价至33港元

Group 1 - Morgan Stanley upgraded Fosun Pharma's (600196)(02196) investment rating from "Market Perform" to "Overweight" after reassessing its R&D pipeline, indicating that the value of its innovative drug portfolio is underestimated [1] - The company is continuously divesting non-core assets, which is expected to enhance its financial capacity and lead to a turnaround in business performance [1] - The target price for H-shares has been raised from HKD 20 to HKD 33, with a forecasted net profit growth of 20% for 2025 and an average annual compound growth rate of 20% for net profit from 2025 to 2027 [1]